|1.||Hitotsuyanagi, Yukio: 5 articles (12/2013 - 06/2003)|
|2.||Takeya, Koichi: 5 articles (12/2013 - 06/2003)|
|3.||Nakagawa, Yoshie: 2 articles (12/2013 - 12/2008)|
|4.||Fukaya, Haruhiko: 2 articles (04/2011 - 12/2008)|
|5.||Kato, Saori: 2 articles (04/2011 - 12/2008)|
|6.||Lee, Ji-Ean: 2 articles (04/2011 - 12/2008)|
|7.||Hasuda, Tomoyo: 1 article (12/2013)|
|8.||Hinosawa, Taka-aki: 1 article (12/2013)|
|9.||Miyazawa, Akihiro: 1 article (12/2013)|
|10.||Xu, Hui-Min: 1 article (03/2012)|
01/01/1986 - "In vitro phase II study of a new cyclic hexapeptide anticancer agent, RA-700 was studied on the human tumor clonogenic assay. "
07/01/2006 - "These results indicate that metronomic scheduling of RA-VII is efficient for cancer treatment. "
07/01/2006 - "We then applied RA-VII for the treatment of tumors in mice. "
11/01/1987 - "The antitumor activity of a newly obtained cyclic hexapeptide, RA-700, from Rubiae Radix was studied using several murine experimental tumor systems. "
01/01/1986 - "Therefore, against the 148 human specimens of various malignancies, the chemosensitivity of RA-700 was tested at the concentrations of 10 micrograms/ml, 1 microgram/ml and 0.1 microgram/ml in continuous exposure schedule for 2 weeks by using the human tumor clonogenic assay. "
11/01/1987 - "In the study of a model of the inhibition of lymph node metastasis using P388 leukemia, the administration of RA-700 at more than 2.5 mg/kg/d i.v. for 7 d resulted in the survival of all animals (5/5) for over 60 d. "
07/01/1993 - "Several aromatic ring substituent modified RA derivatives were prepared from RA-VII (1), RA-V (8) and RA-II (11), and evaluated for cytotoxicity against P388 leukemia and KB cells. "
11/01/1987 - "In P388 leukemia (inoculated intraperitoneally (i.p.), administered i.p.: i.p.-i.p.) the maximal increase in life span (ILSmax) resulting from an administration of RA-700 (4 mg/kg/d for 9 d) was 134% and the therapeutic ratio was 400. "
05/01/1987 - "The antitumor activity of RA-700 was similar to that of deoxy-bouvardin and VCR against P388 leukemia. "
08/01/1993 - "A number of RA-VII derivatives having various amino acids including proline (6), pipecolic acid (11), norvaline (12), ornithine (14), aspartic acid (15) and methionine (20) in place of Ala2 have been synthesized from RA-X methyl ester (3) and evaluated for cytotoxicity to P388 leukemia and KB cells in vitro. "
|3.||Neoplasm Metastasis (Metastasis)
|4.||Lung Neoplasms (Lung Cancer)
04/01/2011 - "Those two methylated analogues showed much weaker cytotoxicity against P-388 leukemia cells than the parent RA-VII."
12/15/2008 - "This analogue, however, showed much weaker cytotoxicity against P-388 leukemia cells than parent RA-VII."
06/18/2003 - "The three epimers showed very weak cytotoxicity on P-388 leukemia cells, which may be because of their conformational differences from the active conformation of RA-VII."
12/15/2013 - "Subsequent macrocyclization of the hexapeptide with EDC · HCl and HOOBt under dilute conditions gave 3. Analogue 3 showed significant cytotoxic activity against human promyelocytic leukemia HL-60 cells and human colon carcinoma HCT-116 cells, but its activity was weaker than that of parent peptide RA-VII (1)."
|10.||Gramicidin (Gramicidin A)